MedWatch

Symphogen's billion dollar deal under new ownership again

For the third time in a very short amount of time, Symphogen has changed its partner in a potential billion dollar deal on the development of six cancer drugs. Good for the project, believes CEO Martin Olin.

Foto: Symphogen

Three partners in a little less than two and a half years. That is the reality for one of Danish Symphogen's largest development deals, after Shire sold its cancer portfolio to the privately owned pharmaceutical company Servier last week.

And even though that type of circulation of partners would probably overwhelm most people, Symphogen's CEO, Martin Olin, reacted positively to the deal.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Headhunter: Afgående Leo-boss var et flop

Det var et fejlskud at ansætte Catherine Mazzacco som adm. direktør for Leo Pharma, vurderer headhunter, der ser afgangen som et naturligt skridt forud for børsnoteringen af Leo Pharma. Til at styre den proces i mål vil bestyrelsen efter alt at dømme skulle til udlandet for at finde den rette profil, lyder det videre.

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier